Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study

Reference

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Kwon DI, Miles BA. Hypopharyngeal carcinoma: do you know your guidelines? Head Neck. 2019;41(3):569–576. doi:10.1002/hed.24752
   PubMed Web of Science ®Google Scholar
• Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–396. doi:10.1016/j.mayocp.2015.12.017
   PubMed Web of Science ®Google Scholar
• Tassler AB, Gooding WE, Ferris RL. Hypopharyngeal cancer treatment: does initial surgery confer survival benefit? Head Neck. 2019;41(7):2167–2173. doi:10.1002/hed.25687
   PubMed Web of Science ®Google Scholar
• Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–683. doi:10.1038/s41571-019-0227-z
   PubMed Web of Science ®Google Scholar
• Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. Cancer Lett. 2020;471:61–71. doi:10.1016/j.canlet.2019.12.007
   PubMed Web of Science ®Google Scholar
• Schoots IG, Padhani AR. Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol. 2020;38(3):531–545. doi:10.1007/s00345-019-02899-0
   PubMed Web of Science ®Google Scholar
• Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study. Biosci Rep. 2019;39(6):Jun. doi:10.1042/BSR20181968
   Web of Science ®Google Scholar
• Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer. 2014;120(17):2735–2741. doi:10.1002/cncr.28769
   PubMed Web of Science ®Google Scholar
• Lee DH, Roh JL, Baek S, et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;149(4):579–586. doi:10.1177/01945998134963.73
   PubMed Web of Science ®Google Scholar
• Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-term survivors of head and neck cancer. Cancer. 2014;120(10):1507–1513. doi:10.1002/cncr.28588
   PubMed Web of Science ®Google Scholar
• Smits HJG, Assili S, Kauw F, Philippens MEP, de Bree R, Dankbaar JW. Prognostic imaging variables for recurrent laryngeal and hypopharyngeal carcinoma treated with primary chemoradiotherapy: a systematic review and meta-analysis. Head Neck. 2021;43(7):2202–2215. doi:10.1002/hed.26698
   PubMed Web of Science ®Google Scholar
• Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–1557. doi:10.1001/jamaoncol.2017.0465
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166
   PubMed Web of Science ®Google Scholar
• Cowens-Alvarado R, Sharpe K, Pratt-Chapman M, et al. Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers. CA Cancer J Clin. 2013;63(3):147–150. doi:10.3322/caac.21183
   PubMed Web of Science ®Google Scholar
• Khanal A, Budhathoki N, Singh VP, Shah BK. Second primary malignancy in bladder carcinoma - A Population-based Study. Anticancer Res. 2017;37(4):2033–2036. doi:10.21873/anticanres.11548
   PubMed Web of Science ®Google Scholar
• Liang F, Zhang S, Xue H, Chen Q. Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies. BMC Cancer. 2017;17(1):871. doi:10.1186/s12885-017-3902-4
   PubMed Web of Science ®Google Scholar
• Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27(3):390–397. doi:10.1093/annonc/mdv616
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi:10.1016/s1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Necchi A, Sonpavde G, Lo Vullo S, et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017;71(2):281–289. doi:10.1016/j.eururo.2016.09.042
   PubMed Web of Science ®Google Scholar
• Pan JJ, Ng WT, Zong JF, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(21):3307–3315. doi:10.1002/cncr.30198
   PubMed Web of Science ®Google Scholar
• Ali AN, Switchenko JM, Kim S, Kowalski J, El-Deiry MW, Beitler JJ. A model and nomogram to predict tumor site origin for squamous cell cancer confined to cervical lymph nodes. Cancer. 2014;120(22):3469–3476. doi:10.1002/cncr.28901
   PubMed Web of Science ®Google Scholar
• Shen W, Sakamoto N, Yang L. Cause-specific mortality prediction model for patients with basaloid squamous cell carcinomas of the head and neck: a competing risk analysis. J Cancer. 2018;9(21):4009–4017. doi:10.7150/jca.20274
   PubMed Web of Science ®Google Scholar
• Tang X, Pang T, Yan WF, Qian WL, Gong YL, Yang ZG. A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma. BMC Cancer. 2020;20(1):1095. doi:10.1186/s12885-020-07599-2
   PubMed Web of Science ®Google Scholar
• Tian S, Li Q, Li R, et al. Development and validation of a prognostic nomogram for hypopharyngeal carcinoma. Front Oncol. 2021;11:696952. doi:10.3389/fonc.2021.696952
   PubMed Web of Science ®Google Scholar
• Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–1331. doi:10.1016/s1470-2045(14)70471-1
   PubMed Web of Science ®Google Scholar
• Kawakita D, Matsuo K. Alcohol and head and neck cancer. Cancer Metastasis Rev. 2017;36(3):425–434. doi:10.1007/s10555-017-9690-0
   PubMed Web of Science ®Google Scholar
• Wookey VB, Appiah AK, Kallam A, Ernani V, Smith LM, Ganti AK. HPV status and survival in non-oropharyngeal squamous cell carcinoma of the head and neck. Anticancer Res. 2019;39(4):1907–1914. doi:10.21873/anticanres.13299
   PubMed Web of Science ®Google Scholar
• Gazdzicka J, Golabek K, Strzelczyk JK, et al. Selected CDKN2A and MDM2 polymorphisms in oral cavity cancer. Acta Biochim Pol. 2020;67(2):213–218. doi:10.18388/abp.2020_5195
   PubMed Web of Science ®Google Scholar
• Misawa K, Mima M, Imai A, et al. The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis. Clin Epigenetics. 2018;10:52. doi:10.1186/s13148-018-0485-0
   PubMed Web of Science ®Google Scholar
• Rashed WM, Saad AM, Al-Husseini MJ, et al. Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study. Endocr Connect. 2018;7:1040–1048. doi:10.1530/EC-18-0304
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Risk of subsequent primary kidney cancer after another malignancy: a Population-based Study. Clin Genitourin Cancer. 2017;15(5):e747–e754. doi:10.1016/j.clgc.2017.02.004
   PubMed Web of Science ®Google Scholar
• Bezak E, Takam R, Yeoh E, Marcu LG. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy. Phys Med. 2017;42:253–258. doi:10.1016/j.ejmp.2017.02.018
   PubMed Web of Science ®Google Scholar
• Chowdhry AK, Fung C, Chowdhry VK, et al. A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma. Leuk Lymphoma. 2018;59(5):1180–1187. doi:10.1080/10428194.2017.1369063
   PubMed Web of Science ®Google Scholar
• Morais S, Antunes L, Bento MJ, Lunet N. Risk of second primary cancers among patients with a first primary gastric cancer: a population-based study in North Portugal. Cancer Epidemiol. 2017;50:85–91. doi:10.1016/j.canep.2017.08.007
   PubMed Web of Science ®Google Scholar
• Zhuang L, Yan X, Meng Z. Second primary malignancy in patients with cholangiocarcinoma: a population-based study. Cancer Manag Res. 2019;11:1969–1983. doi:10.2147/CMAR.S187614
   PubMed Web of Science ®Google Scholar
• Eckel HE, Bradley PJ. Treatment options for hypopharyngeal cancer. Adv Otorhinolaryngol. 2019;83:47–53. doi:10.1159/000492308
   PubMedGoogle Scholar
• Li R, Zhang Y, Ma B, Tan K, Lynn HS, Wu Z. Survival analysis of second primary malignancies after cervical cancer using a competing risk model: implications for prevention and surveillance. Ann Transl Med. 2021;9(3):239. doi:10.21037/atm-20-2003
   PubMed Web of Science ®Google Scholar